Nanologica Past Earnings Performance
Past criteria checks 0/6
Nanologica's earnings have been declining at an average annual rate of -28.3%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 11.4% per year.
Key information
-28.3%
Earnings growth rate
-8.8%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | -11.4% |
| Return on equity | n/a |
| Net Margin | -1,608.7% |
| Next Earnings Update | 26 Apr 2024 |
Recent past performance updates
Recent updates
Nanologica (STO:NICA) Is Making Moderate Use Of Debt
Oct 10
Is Nanologica AB (publ) (STO:NICA) Trading At A 40% Discount?
Jun 12Does Nanologica (STO:NICA) Have A Healthy Balance Sheet?
Oct 20Nanologica (STO:NICA) Is Making Moderate Use Of Debt
Jun 23Is Nanologica (NGM:NICA) A Risky Investment?
Jan 03Is Nanologica (NGM:NICA) Weighed On By Its Debt Load?
Jun 14Shareholders Are Thrilled That The Nanologica (NGM:NICA) Share Price Increased 115%
Feb 23Revenue & Expenses BreakdownBeta
How Nanologica makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 5 | -75 | 41 | 0 |
| 30 Sep 23 | 6 | -53 | 38 | 0 |
| 30 Jun 23 | 7 | -53 | 39 | 0 |
| 31 Mar 23 | 7 | -51 | 38 | 0 |
| 31 Dec 22 | 6 | -55 | 42 | 0 |
| 30 Sep 22 | 5 | -56 | 37 | 0 |
| 30 Jun 22 | 6 | -57 | 39 | 0 |
| 31 Mar 22 | 9 | -53 | 37 | 0 |
| 31 Dec 21 | 15 | -45 | 34 | 0 |
| 30 Sep 21 | 21 | -35 | 32 | 0 |
| 30 Jun 21 | 21 | -28 | 31 | 0 |
| 31 Mar 21 | 21 | -23 | 31 | 0 |
| 31 Dec 20 | 18 | -22 | 30 | 0 |
| 30 Sep 20 | 14 | -24 | 27 | 0 |
| 30 Jun 20 | 14 | -24 | 26 | 0 |
| 31 Mar 20 | 14 | -23 | 27 | 0 |
| 31 Dec 19 | 12 | -21 | 23 | 0 |
| 30 Sep 19 | 12 | -18 | 23 | 0 |
| 30 Jun 19 | 11 | -18 | 22 | 0 |
| 31 Mar 19 | 8 | -19 | 20 | 0 |
| 31 Dec 18 | 6 | -21 | 19 | 0 |
| 30 Sep 18 | 7 | -18 | 21 | 0 |
| 30 Jun 18 | 6 | -18 | 21 | 0 |
| 31 Mar 18 | 5 | -19 | 21 | 0 |
| 31 Dec 17 | 5 | -20 | 23 | 0 |
| 30 Sep 17 | 3 | -22 | 23 | 0 |
| 30 Jun 17 | 4 | -24 | 23 | 0 |
| 31 Mar 17 | 4 | -24 | 23 | 0 |
| 31 Dec 16 | 4 | -22 | 22 | 0 |
| 30 Sep 16 | 5 | -23 | 22 | 0 |
| 30 Jun 16 | 5 | -21 | 21 | 0 |
| 31 Mar 16 | 7 | -18 | 21 | 0 |
| 31 Dec 15 | 9 | -14 | 19 | 0 |
| 30 Sep 15 | 8 | -14 | 19 | 0 |
| 30 Jun 15 | 9 | -15 | 20 | 0 |
| 31 Mar 15 | 7 | -14 | 18 | 0 |
| 31 Dec 14 | 7 | -15 | 19 | 0 |
| 31 Dec 13 | 5 | -10 | 14 | 0 |
Quality Earnings: NICA is currently unprofitable.
Growing Profit Margin: NICA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NICA is unprofitable, and losses have increased over the past 5 years at a rate of 28.3% per year.
Accelerating Growth: Unable to compare NICA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NICA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.7%).
Return on Equity
High ROE: NICA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.